Screener
Tarsus Pharmaceuticals, Inc. TARS Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Amortization of intangible assets | 480 | 480 |
| Amortization of debt-related costs | 325 | 285 |
| Loss on disposal of property and equipment | 183 | — |
| Stock-based compensation | 25,256 | 15,163 |
| Non-cash lease expense | 169 | 323 |
| Gain on exchange of long-term investments | (2,812) | — |
| Net amortization/accretion of marketable securities | (1,611) | (3,023) |
| Unrealized (gain) loss from transactions denominated in a foreign currency | (10) | 26 |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s stock-based comp?
- Tarsus Pharmaceuticals, Inc. (TARS) reported stock-based comp of $13.29M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s stock-based comp changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s stock-based comp increased by 61.4% year-over-year, from $8.23M to $13.29M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s stock-based comp has grown at a 49.0% compound annual growth rate (CAGR), from $8.46M to $41.72M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude